378 related articles for article (PubMed ID: 19560694)
1. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
[TBL] [Abstract][Full Text] [Related]
2. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
[TBL] [Abstract][Full Text] [Related]
4. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
[TBL] [Abstract][Full Text] [Related]
7. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
10. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
[TBL] [Abstract][Full Text] [Related]
11. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
14. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
[TBL] [Abstract][Full Text] [Related]
16. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
[TBL] [Abstract][Full Text] [Related]
19. Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection.
Večerić-Haler Ž; Bizjak B; Romozi K; Arnol M
Clin Nephrol; 2017 Supplement 1; 88(13):126-130. PubMed ID: 28601128
[TBL] [Abstract][Full Text] [Related]
20. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
